Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ex Vivo CRISPR-Edited Donor Liver Transplant
NCT07053488Phase 2Recruiting
- Sponsor
- American Organ Transplant and Cancer Research Institute
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in liver disease and acute liver failure (ALF), sponsored by American Organ Transplant and Cancer Research Institute. Primary endpoints: Incidence of Grade ≥3 Treatment-Emergent Adverse Events, Feasibility of Ex Vivo HLA Gene Editing and 1 more. Started Jun 2025; status: recruiting.
02
Conditions
liver diseaseacute liver failure (ALF)
Beyond the preview
Go deeper on NCT07053488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053488.